JP2023534037A5 - - Google Patents

Info

Publication number
JP2023534037A5
JP2023534037A5 JP2023502675A JP2023502675A JP2023534037A5 JP 2023534037 A5 JP2023534037 A5 JP 2023534037A5 JP 2023502675 A JP2023502675 A JP 2023502675A JP 2023502675 A JP2023502675 A JP 2023502675A JP 2023534037 A5 JP2023534037 A5 JP 2023534037A5
Authority
JP
Japan
Prior art keywords
sequence
mirna
vector
hmfn2
coding sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041406 external-priority patent/WO2022015715A1/en
Publication of JP2023534037A publication Critical patent/JP2023534037A/ja
Publication of JP2023534037A5 publication Critical patent/JP2023534037A5/ja
Pending legal-status Critical Current

Links

JP2023502675A 2020-07-13 2021-07-13 シャルコー・マリー・トゥース病の治療に有用な組成物 Pending JP2023534037A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051336P 2020-07-13 2020-07-13
US63/051,336 2020-07-13
US202163173045P 2021-04-09 2021-04-09
US63/173,045 2021-04-09
PCT/US2021/041406 WO2022015715A1 (en) 2020-07-13 2021-07-13 Compositions useful for treatment of charcot-marie-tooth disease

Publications (2)

Publication Number Publication Date
JP2023534037A JP2023534037A (ja) 2023-08-07
JP2023534037A5 true JP2023534037A5 (cg-RX-API-DMAC7.html) 2024-07-23

Family

ID=77317406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502675A Pending JP2023534037A (ja) 2020-07-13 2021-07-13 シャルコー・マリー・トゥース病の治療に有用な組成物

Country Status (14)

Country Link
US (1) US20230270884A1 (cg-RX-API-DMAC7.html)
EP (1) EP4179097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023534037A (cg-RX-API-DMAC7.html)
KR (1) KR20230038503A (cg-RX-API-DMAC7.html)
CN (1) CN116438311A (cg-RX-API-DMAC7.html)
AU (1) AU2021309645A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000578A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185281A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001500A2 (cg-RX-API-DMAC7.html)
IL (1) IL299762A (cg-RX-API-DMAC7.html)
MX (1) MX2023000658A (cg-RX-API-DMAC7.html)
TW (1) TW202216244A (cg-RX-API-DMAC7.html)
WO (1) WO2022015715A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300505B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
PE20241891A1 (es) * 2021-09-01 2024-09-19 Jaguar Gene Therapy Llc Vectores y viriones adenoasociados para tratar la galactosemia y metodos de uso y fabricacion
WO2023049846A1 (en) * 2021-09-24 2023-03-30 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024155966A1 (en) * 2023-01-20 2024-07-25 Loma Linda University Health Methods and compositions for treatment of niemann-pick disease type c and charcot-marie-tooth disease
WO2024261139A1 (en) 2023-06-21 2024-12-26 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Variants of mfn2 and their use in the treatment/prevention of diseases associated with alterations in endoplasmatic reticulum function
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
US11015174B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3992283A1 (en) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
WO2018168956A1 (ja) 2017-03-16 2018-09-20 株式会社デンソー 自己位置推定装置
IL276859B2 (en) 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3768695A4 (en) 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
AU2019328270B2 (en) * 2018-08-29 2026-02-26 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant GARS protein
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
CN106488984B (zh) 一种治疗周围神经病变以及运动神经元疾病的方法
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
US20220281923A1 (en) Aav capsid variants for gene therapy
JP2022531809A (ja) ATPase媒介性疾患の処置のための組成物および方法
KR20210096168A (ko) 신경퇴행성 질환을 위한 유전자 요법
CN113747926A (zh) 用于肌肉表达的杂合启动子
US20210180084A1 (en) Gene therapy vectors comprising s/mar sequences
JP2018533976A5 (cg-RX-API-DMAC7.html)
Gan et al. Gene delivery with viral vectors for cerebrovascular diseases
JP2020527167A5 (cg-RX-API-DMAC7.html)
CN114276419B (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
US20230175015A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2020510433A5 (cg-RX-API-DMAC7.html)
CN114516901B (zh) 一种神经系统高亲和性的aav载体及其应用
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
JP2022514271A5 (cg-RX-API-DMAC7.html)
JP2022523320A5 (cg-RX-API-DMAC7.html)
US12416020B2 (en) Plasmid encoding a TLR3 and Fc fusion protein
CN111093716A (zh) 用于治疗神经性疼痛的方法和组合物
RU2021117249A (ru) Модулирующие полинуклеотиды
RU2021102051A (ru) Синергетическое действие SMN1 и miR-23a при лечении спинальной мышечной атрофии
RU2021105703A (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение
Miyake et al. 830. Direct Comparison of Adeno-Associated Virus Serotypes for Global Gene Transfer into the CNS across the BBB after Neonatal Systemic Delivery